Molecular Partners AG
SIX:MOLN

Watchlist Manager
Molecular Partners AG Logo
Molecular Partners AG
SIX:MOLN
Watchlist
Price: 4.59 CHF 7.75% Market Closed
Market Cap: 185.3m CHF
Have any thoughts about
Molecular Partners AG?
Write Note

Operating Margin
Molecular Partners AG

-725.4%
Current
-457%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-725.4%
=
Operating Profit
-75.5m
/
Revenue
10.4m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
CH
Molecular Partners AG
SIX:MOLN
185.3m CHF
-725%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
309B USD
28%
US
Amgen Inc
NASDAQ:AMGN
141B USD
19%
US
Gilead Sciences Inc
NASDAQ:GILD
116B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
103.5B USD
40%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
134.4B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-22%
Country CH
Market Cap 185.3m CHF
Operating Margin
-725%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 309B USD
Operating Margin
28%
Country US
Market Cap 141B USD
Operating Margin
19%
Country US
Market Cap 116B USD
Operating Margin
38%
Country US
Market Cap 103.5B USD
Operating Margin
40%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 134.4B AUD
Operating Margin
26%
Country US
Market Cap 78.7B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 36B EUR
Operating Margin
-22%
No Stocks Found

Molecular Partners AG
Glance View

Market Cap
185.3m CHF
Industry
Biotechnology

Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 163 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

MOLN Intrinsic Value
2.91 CHF
Overvaluation 37%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-725.4%
=
Operating Profit
-75.5m
/
Revenue
10.4m
What is the Operating Margin of Molecular Partners AG?

Based on Molecular Partners AG's most recent financial statements, the company has Operating Margin of -725.4%.